Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,504 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07233291RecruitingPhase 2
Roflumilast pills for moderate to severe psoriasis in adults
This study tests an oral medicine called roflumilast for adults with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective when taken by mouth, and you can join if you have not used other systemic treatments recently.
Al Mansurah, Dakahlia GovernorateAges 18 years+ - NCT07235904RecruitingPhase 4
Mirikizumab vs standard treatment for newly diagnosed ulcerative colitis
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
KielAges 18–75 - NCT07241117RecruitingPhase 4
CHEST: Helping clinics use SMART for asthma
This study tests a program to help community health clinics use a special asthma treatment approach called SMART. The goal is to see if it improves asthma care and reduces flare-ups.
St Louis, MissouriAges 12 years+ - NCT07244510RecruitingPhase 2
New Treatment for Moderate to Severe Hidradenitis Suppurativa
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
Samsun, TurkeyAges 18 years+ - NCT05022459Recruiting
Prevent bleeding in kids with Hemophilia A who play sports
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
Little Rock, ArkansasAges 6–19 - NCT06480838Recruiting
Brain blood flow and thinking after traumatic brain injury
This study looks at how the brain controls its own blood flow after a moderate to severe traumatic brain injury (TBI). It uses MRI scans and thinking tests to understand recovery and help improve care for people like you.
Dallas, TexasAges 18–80 - NCT07265284RecruitingPhase 3
IBI112 for teens with moderate to severe plaque psoriasis
This study tests a new medicine called IBI112 for teens aged 12–18 with moderate to severe plaque psoriasis. It aims to see if the medicine is safe and can help clear skin better than placebo.
Beijing, Beijing MunicipalityAges 12–18 - NCT07284446Recruiting
Depression, memory, and outcomes in heart failure patients
This study looks at how depression and memory problems affect recovery in people hospitalized with worsening chronic heart failure. It aims to find better ways to support patients during their hospital stay.
KaunasAges 18–85 - NCT07287644RecruitingPhase 2/Phase 3
Study of BFB759 for moderate to severe hidradenitis suppurativa
This trial tests a new medication, BFB759, to see if it can help people with moderate to severe hidradenitis suppurativa (a skin condition that causes painful bumps and abscesses) when antibiotics haven't worked well enough. It is designed for adults whose symptoms are not well controlled with current treatments.
Phoenix, ArizonaAges 18–75 - NCT07293962RecruitingPhase 2
Liquid S-PRF for gum disease treatment
This study tests whether a special liquid made from your own blood (called liquid S-PRF) can improve gum health during deep cleaning for people with advanced gum disease. It lasts 3 months and may help reduce inflammation and promote healing without surgery.
Jenjarum, SelangorAges 18–65 - NCT07297602RecruitingPhase 2
Oral roflumilast for moderate to severe eczema in teens and adults
This study tests an oral medicine called roflumilast to see if it helps treat moderate to severe eczema in people aged 12 and up who haven't used other systemic treatments recently. It's a pilot study to check both safety and how well it works.
Al Mansurah, Dakahlia GovernorateAges 12 years+ - NCT07302048Recruiting
Mobile pain management support for kids with intellectual disabilities
This study tests a mobile program that helps manage pain in children and young adults with intellectual disabilities, autism, or multiple disabilities. It aims to see if the program improves pain relief and works well with their care team.
BrestAges Up to 24 years - NCT07330934RecruitingPhase 2
Study of IBI356 for moderate to severe eczema
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07339332RecruitingEarly Phase 1
CAR-T cell therapy for moderate to severe lupus
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
Wuhan, HubeiAges 18–65 - NCT07225569RecruitingPhase 2
Study of a new drug for moderate to severe hidradenitis suppurativa
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
Scottsdale, ArizonaAges 18 years+ - NCT07184931RecruitingPhase 3
Testing duvakitug for active Crohn's disease
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Peoria, ArizonaAges 16–80 - NCT07355075RecruitingPhase 2
Study of GX-03 cream for moderate to severe eczema
This trial tests an investigational cream called GX-03 for adults with moderate to severe eczema (atopic dermatitis). Participants apply the cream to affected skin daily, and the study compares it to a placebo cream to see if it improves symptoms safely.
Irving, TexasAges 18–80 - NCT07374471RecruitingPhase 1/Phase 2
Testing MB-001 for moderate to severe ulcerative colitis
This study tests an investigational drug called MB-001 for people with moderate to severe ulcerative colitis who have already tried standard treatments without success. It aims to see if the drug is safe and helps control inflammation.
ChisinauAges 18–75 - NCT07385131Recruiting
Steroid before infliximab for inflammatory bowel disease
This study tests whether giving a steroid (dexamethasone) before an infliximab infusion can prevent allergic reactions in people with moderate-to-severe Crohn's disease or ulcerative colitis. If you qualify, you will receive either the steroid or a placebo before your infliximab treatment.
Hangzhou, ZhejiangAges 14–80 - NCT00576069Recruiting
Study airflow limits in moderate asthma
This trial looks at why airflow is limited in people with moderate-to-severe persistent asthma who are already on stable treatment. It may help researchers better understand what drives breathing trouble and how to target it.
Lakewood, CaliforniaAges 10–95 - NCT07213973RecruitingPhase 2
Study of povorcitinib for teens with hidradenitis suppurativa
This trial tests an oral medication called povorcitinib for adolescents aged 12–17 with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with standard treatments like antibiotics. It aims to see how well the drug works and if it's safe.
Birmingham, AlabamaAges 12–17 - NCT07399067RecruitingPhase 2
Testing IBI3002 for moderate to severe eczema
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Beijing, Beijing MunicipalityAges 18–75 - NCT07408024RecruitingPhase 2
TollB-001 tablets for moderate to severe rheumatoid arthritis
This trial tests an experimental tablet, TollB-001, for people with moderate to severe rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and effective.
Bengbu, AnhuiAges 18–70 - NCT07412860Recruiting
Eye drop test for moderate to severe dry eye
This trial tests a new eye drop (FBV_01) compared to a standard hyaluronic acid eye drop for people with moderate to severe dry eye. The goal is to see if the new drop provides better relief.
Cagliari, CAAges 18 years+
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,504 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.